Stoke Therapeutics, Inc.

Stoke Therapeutics, Inc. is a clinical-stage biotechnology company that develops antisense oligonucleotide medicines to address the genetic causes of severe diseases. Utilizing its Targeted Augmentation of Nuclear Gene Output platform, the company restores protein expression in haploinsufficiency disorders affecting the central nervous system and the eye. Its lead product candidate is zorevunersen, an investigational treatment for Dravet syndrome, and its pipeline includes STK-002 for autosomal dominant optic atrophy alongside preclinical research programs. Stoke Therapeutics develops these therapies for patients with rare genetic conditions and collaborates with biopharmaceutical partners including Biogen and Acadia Pharmaceuticals.

The company conducts clinical trials across multiple countries, including completed studies in the United States and the United Kingdom as well as an ongoing global Phase 3 study. Stoke Therapeutics also maintains a collaboration covering development and commercialization rights outside the United States, Canada, and Mexico. The company's principal executive offices are located in Bedford, Massachusetts.

Summary of the business section of Stoke Therapeutics's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of December 31, 2025, we had 170 employees, 49 of whom have an M.D.”